[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354995-105":59,"doc-detail-354995-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-pkmyt1-enhances-antitumor-immune-responses-to-pd-l1-blockade-in-castration-resistant-prostate-cancer","Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer","","Immunotherapy efficacy remains limited in castration-resistant prostate cancer (CRPC) due to an immunologically “cold” tumor microenvironment with scarce T-cell infiltration. This study used bioinformatic analyses of PKMYT1 expression in public datasets, validated protein expression in a clinical cohort, and investigated mechanisms in cell lines and mouse models. PKMYT1 inhibition activated the cGAS-STING pathway, boosted type I/II interferon signaling, increased CCL5 and CXCL10, enhanced CD8+ T-cell infiltration, and improved responses to PD-L1 blockade, suppressing tumors in vivo.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-pkmyt1-enhances-antitumor-immune-responses-to-pd-l1-blockade-in-castration-resistant-prostate-cancer/354995/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-pkmyt1-enhances-antitumor-immune-responses-to-pd-l1-blockade-in-castration-resistant-prostate-cancer/354995.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is immunotherapy limited in castration-resistant prostate cancer (CRPC)?","Question",{"text":112,"@type":113},"Efficacy is limited because CRPC often has an immunologically “cold” tumor microenvironment with few tumor-infiltrating T cells, especially CD8+ T cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the role of PKMYT1 in CRPC and immune evasion?",{"text":117,"@type":113},"PKMYT1 is significantly overexpressed in CRPC and high expression correlates with suppressed antitumor immunity and poorer clinical responses to immune checkpoint blockade.",{"name":119,"@type":110,"acceptedAnswer":120},"How does PKMYT1 inhibition improve responses to PD-L1 blockade?",{"text":121,"@type":113},"PKMYT1 inhibition activates the cGAS-STING pathway, potentiates type I and II interferon signaling, upregulates chemokines such as CCL5 and CXCL10, increases activated CD8+ T-cell infiltration, and enhances tumor suppression in vivo, both alone and with PD-L1 blockade.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354995,1790143599,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Open access Original research  \n Targeting PKMYT1 enhances antitumor  \nimmune responses to PD-L1 blockade in castration-resistant prostate cancer  \nLin Gao  ,1,2 Baozhen Wang  ,3 Hui Liu  ,4 Ping Liu  ,3 Long Liu  ,4 Jingying Han  ,3 Xin Wang  ,3 Baokai Dou  ,5 Feifei Sun  ,6 Wenyao Liu  ,4 Xinpei Wang  ,3 Tingting Feng  ,7 Ru Zhao  ,4 Xiaorong Yang  ,8 Weiwen Chen  ,1 Jing Hu  ,4 Bo Han  6  \nTo cite: Gao L, Wang B, Liu H, et al. Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. Journal for ImmunoTherapy of Cancer 2026;14:e013247 . doi:10 . 1136/ jitc-2025-013247  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013247](jitc-2025-013247)) .  \nAccepted 16 January 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Bo Han;  \n[hanbo@pkuph.edu.cn](hanbo@pkuph.edu.cn)  \nDr Jing Hu;  \n[201420420@mail.sdu.edu.cn](201420420@mail.sdu.edu.cn)  \nABSTRACT  \nBackground Although immunotherapy has revolutionized cancer treatment, its efficacy in castration-resistant prostate cancer (CRPC) remains limited, largely due to an immunologically “cold” tumor microenvironment with scarce T-cell infiltration. Unraveling the molecular mechanisms underlying immune evasion and developing novel strategies to activate innate antitumor immunity are therefore critical to overcoming immunotherapy resistance in CRPC.  \nMethods Using bioinformatic approaches, we analyzed the protein kinase membrane-associated tyrosine/ threonine 1 (PKMYT1) expression and its correlation with immune cell infiltration and response to immune checkpoint blockade (ICB) in public databases.  \nPKMYT1 protein expression was further evaluated via immunohistochemistry in a clinical cohort of prostate cancer (PCa) specimens. Mechanistic investigations were conducted in PCa cell lines and mouse models. The immunological impact of PKMYT1 inhibition was delineated using single-cell RNA sequencing, and the therapeutic efficacy of RP-6306, either as monotherapy orin combination with programmed death-ligand 1 (PD-L1) blockade, was evaluated in syngeneic mouse models. Results PKMYT1 expression was significantly overexpressed in CRPC compared with primary PCa.  \nHigh PKMYT1 expression correlated with a suppressed antitumor immunity and poor clinical response to ICB. Mechanistically, PKMYT1 inhibition activated the cyclic guanosine monophosphate-adenosine monophosphate adenosine synthase (cGAS)-stimulator of interferon genes (STING) pathway, potentiated both type I and II interferon signaling, and upregulated chemokines, including CCL5 and CXCL10 . The selective PKMYT1 inhibitor, RP-6306, enhanced the efficacy of ICB in the presence of CD8+ T cells. Treatment with a PKMYT1 inhibitor alone or in combination with PD-L1 blockade significantly increased the infiltration of activated CD8+ T cells and induced significant tumor suppression in vivo.  \nConclusion PKMYT1 is a pivotal dual regulator of tumor progression and immune evasion in CRPC. Our findings provide a compelling preclinical rationale for targeting PKMYT1 as a novel strategy to reprogram the tumor immune microenvironment and overcome resistance to immunotherapy.  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Prostate cancer represents a major global health burden, ranking as one of the most prevalent cancers diagnosed in men. The development of castration-resistant prostate cancer (CRPC) following long-term androgen deprivation therapy remains a critical clinical challenge. Although immune checkpoint blockade (ICB) confers substantial benefits to multiple cancer subtypes, its efficacy in improving clinical outcomes for patients with CRPC has thus far bee","cbCaihPUS983y7bd","https://ap.wps.com/l/cbCaihPUS983y7bd","pdf",9622417,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Background","[{\"question\":\"Why is immunotherapy limited in castration-resistant prostate cancer (CRPC)?\",\"answer\":\"Efficacy is limited because CRPC often has an immunologically “cold” tumor microenvironment with few tumor-infiltrating T cells, especially CD8+ T cells.\"},{\"question\":\"What is the role of PKMYT1 in CRPC and immune evasion?\",\"answer\":\"PKMYT1 is significantly overexpressed in CRPC and high expression correlates with suppressed antitumor immunity and poorer clinical responses to immune checkpoint blockade.\"},{\"question\":\"How does PKMYT1 inhibition improve responses to PD-L1 blockade?\",\"answer\":\"PKMYT1 inhibition activates the cGAS-STING pathway, potentiates type I and II interferon signaling, upregulates chemokines such as CCL5 and CXCL10, increases activated CD8+ T-cell infiltration, and enhances tumor suppression in vivo, both alone and with PD-L1 blockade.\"}]","Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer | PDF",1790115313,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c43dcb27d3fb3d85ac6491f27bbddffa.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3a3f2676288649a17c6250902719208.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/067d924b0d0af438218604c34fe7a44b.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d7709fdf0a8fd8def77c012707cee63.webp",980,1306]